Michael J Sorich Selected Research

atezolizumab

3/2022	The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy.
1/2022	Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
1/2022	Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy.
1/2022	Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials: Smoking and immunotherapy efficacy in lung cancer.
7/2021	Reply to Auclin et al. Comment on "Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176".
4/2021	Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer.
3/2021	Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
1/2021	Effect of concomitant use of antihypertensives and immune check point inhibitors on cancer outcomes.
12/2020	Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
12/2020	Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, et al. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Eur Urol 2020;78:540-3.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael J Sorich Research Topics

Disease

20	Neoplasms (Cancer) 01/2022 - 04/2008
15	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2022 - 10/2018
10	Melanoma (Melanoma, Malignant) 01/2021 - 09/2017
9	Breast Neoplasms (Breast Cancer) 08/2021 - 01/2019
7	Rheumatoid Arthritis 06/2022 - 07/2012
5	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 12/2015
4	Carcinoma (Carcinomatosis) 01/2022 - 10/2020
4	Lung Neoplasms (Lung Cancer) 01/2022 - 08/2019
4	Exanthema (Rash) 01/2021 - 01/2020
4	Diarrhea 12/2019 - 06/2012
4	Arthritis (Polyarthritis) 01/2016 - 07/2012
3	Dysbiosis 01/2022 - 10/2020
3	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 09/2020
3	Hypertension (High Blood Pressure) 01/2020 - 01/2018
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2018 - 01/2016
3	Autism Spectrum Disorder 11/2011 - 12/2009
3	Autistic Disorder (Autism) 11/2011 - 12/2009
2	Liver Diseases (Liver Disease) 01/2022 - 01/2021
2	Non-alcoholic Fatty Liver Disease 01/2022 - 06/2020
2	Hand-Foot Syndrome 01/2022 - 01/2020
2	Neutropenia 08/2021 - 06/2012
2	Obesity 10/2020 - 01/2020
2	Infections 10/2020 - 01/2020
2	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2020
2	Proteinuria 01/2018 - 01/2016
2	Drug-Related Side Effects and Adverse Reactions 04/2015 - 09/2012
1	Fibrosarcoma 01/2021
1	Pathologic Processes 06/2020
1	Vomiting 01/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Inflammation (Inflammations) 01/2020
1	Disease Progression 01/2020
1	Nausea 01/2020
1	Eye Diseases (Eye Disease) 01/2020
1	Dyslipidemias (Dyslipidemia) 01/2020
1	Thrombocytopenia (Thrombopenia) 01/2020
1	Arthralgia (Joint Pain) 01/2019
1	Body Weight (Weight, Body) 12/2018

Drug/Important Bio-Agent (IBA)

17	atezolizumabIBA 03/2022 - 08/2019
14	Immune Checkpoint InhibitorsIBA 03/2022 - 09/2017
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2009
6	Antirheumatic Agents (DMARD)IBA 01/2021 - 07/2012
6	VemurafenibIBA 01/2021 - 01/2019
5	Proton Pump InhibitorsIBA 01/2022 - 10/2020
5	cobimetinibIBA 01/2021 - 01/2019
5	Pharmaceutical PreparationsIBA 01/2021 - 04/2008
4	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 09/2020
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2019 - 01/2016
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 10/2020
3	AfatinibIBA 01/2021 - 10/2018
3	Docetaxel (Taxotere)FDA Link 12/2020 - 01/2019
3	Ado-Trastuzumab EmtansineIBA 01/2020 - 08/2019
2	MicroRNAs (MicroRNA)IBA 01/2022 - 06/2020
2	Bevacizumab (Avastin)FDA Link 01/2022 - 12/2019
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 01/2020
2	abemaciclibIBA 08/2021 - 01/2021
2	Antihypertensive Agents (Antihypertensives)IBA 01/2021 - 01/2021
2	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2021
2	dabrafenibIBA 01/2020 - 12/2018
2	pertuzumabIBA 01/2020 - 01/2019
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 01/2020
2	human ERBB2 proteinIBA 01/2020 - 01/2020
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 01/2019
2	Lapatinib (GW572016)FDA Link 01/2020 - 01/2020
2	Sunitinib (Sutent)FDA Link 01/2018 - 01/2016
2	pazopanib FDA Link 01/2018 - 01/2016
2	Monoclonal AntibodiesIBA 03/2016 - 12/2015
2	Biological ProductsIBA 02/2016 - 12/2009
2	Methotrexate (Mexate)FDA LinkGeneric 04/2015 - 04/2008
2	Cytochrome P-450 CYP2C19IBA 12/2014 - 12/2013
2	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 07/2012 - 07/2012
1	Gonadal Steroid Hormones (Sex Hormones)IBA 06/2022
1	tocilizumab (atlizumab)FDA Link 06/2022
1	AlbuminsIBA 01/2022
1	Carboplatin (JM8)FDA LinkGeneric 01/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Phosphotransferases (Kinase)IBA 07/2021
1	Hormones (Hormone)IBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Tyrosine Kinase InhibitorsIBA 10/2020
1	trametinibIBA 01/2020
1	taxaneIBA 01/2020
1	Capecitabine (Xeloda)FDA Link 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2019
1	RamucirumabIBA 12/2019
1	pembrolizumabIBA 08/2019
1	Axitinib (AG 013736)IBA 01/2019
1	Cytochrome P-450 CYP2C8IBA 12/2018
1	Cytochrome P-450 CYP3AIBA 12/2018
1	Hemoglobins (Hemoglobin)IBA 10/2018
1	Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA 01/2018
1	IpilimumabIBA 09/2017
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2016
1	AngiotensinsIBA 05/2016

Therapy/Procedure

28	Therapeutics 01/2022 - 04/2008
8	Drug Therapy (Chemotherapy) 03/2022 - 01/2016
5	Immunotherapy 01/2022 - 01/2020
2	Drug Tapering 01/2021 - 06/2012